Point32Health, the parent company of Harvard Pilgrim Health Care and Tufts Health Plan, and Foundation Medicine, have entered into a value-based agreement to make FoundationOne®CDx and FoundationOne®Liquid CDx, FDA-approved comprehensive genomic profiling tests, available to Point32Health members with advanced cancer, including Medicaid members.
If you’ve been following the saga of drug shortages in this publication, you know how America’s cancer institutions are scrambling to obtain platinum-based drugs for their patients.
